Pembrolizumab

Red

Brand Name(s):KEYTRUDA

Indication:Untreated metastatic colorectal cancer

Other licensed indications

Rationale:1,2,3

Considered:Aug-15

Review Date:Jul-26

Comments:
NICE TA709
Pembrolizumab is recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults only if:
* pembrolizumab is stopped after 2 years and no documented disease progression
* the company provides pembrolizumab according to the commercial arrangement
June 21

NICE TA683 recommend pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no EGFR or ALK +ve mutations, only if it is stopped at 2 years of uninterrupted treatment, or earlier.
March ’21.

NICE TA661 Recommends pembrolizumab for untreated metastatitic/unresectable recurrent head and neck squamous cell carcinoma in adults with PD-L1+ve tumours.
NICE TA650 does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults. Drug Safety Update
Reports of organ transplant rejection
Jul-17
…………………………
NICE TA428
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
January 2017